News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 364
- Sources here
- 16
- Companies here
- 14
Search results
Stored financial headlines
Active search
364 matching headlines
Ticker or company: BOSMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Boston Scientific (NYSE: BSX) director adds 5,000 shares in open-market buy
Edward J. Ludwig, a director at Boston Scientific Corp (NYSE: BSX), purchased 5,000 shares of common stock on July 31, 2026, at an average price of $45.4799 per share. This open-market transaction increased his direct holdings to 30,359 shares and was not executed under …
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
Boston Scientific (BSX) EVP boosts company stock stake through 401(k) rebalance
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), acquired 64,198 shares of company common stock on July 31, 2026, through a 401(k) rebalance at $46.73 per share. This discretionary transaction increases his indirect holdings in the 401(k) to 64,198 shares, …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific 2Q 2026: Revenue $5.44B, EPS $0.61— 10-Q Summary
Boston Scientific (BSX) reported its second-quarter 2026 results, with revenue reaching $5.44 billion and diluted EPS of $0.61, marking increases of 7.5% and 15.1% respectively compared to the prior year. The growth was primarily driven by strong performance in Interventional Cardiology, Vascular Therapies, and …
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
[10-Q] BOSTON SCIENTIFIC CORP Quarterly Earnings Report
Boston Scientific (BSX) released its Q2 2026 Quarterly Earnings Report, detailing a 7.5% increase in reported net sales for the quarter and a 9.5% increase for the first six months of 2026, primarily driven by growth in its Interventional Cardiology, Vascular Therapies, and Electrophysiology …
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook
BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter's revenue guidance of $5.27 billion …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%BOS Better Online Solutions Ltd (BOSC) Financial Health: Profitability & Balance Sheet Analysis
BOS Better Online Solutions Ltd (BOSC) has a stable financial status with a current financial score of 5.98, ranking 161 out of 181 in its industry. Despite this, its operating efficiency is low, and it reported a year-over-year decrease of 24.21% in revenue and …
BOSC
main company
Sharemaestro market context
Price below Trend Line
52 weeks -6.2%
The Beat: Boston Scientific plans $500M cuts, NatureWorks seeks CEO, Gravie expands focus
Boston Scientific is planning $500 million in cost reductions. NatureWorks, a bioplastics manufacturer backed by Cargill, is searching for a new CEO. Gravie, a company that provides health benefits, is increasing its hiring efforts to target a new type of customer.
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says
Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
Boston Scientific Corporation BSX delivered a solid second quarter, but management highlighted a tougher path ahead as pressure in WATCHMAN and electrophysiology changed the company's near-term outlook. Executives reduced full-year expectations while emphasizing cost actions and future product catalysts. The call focused on market …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%TD Cowen Adjusts Price Target on Boston Scientific to $56 From $61, Maintains Buy Rating
TD Cowen has revised its price target for Boston Scientific (NYSE:BSX) to $56, down from the previous $61, while reaffirming a Buy rating on the stock. This adjustment comes despite the retained positive outlook from the analyst firm.
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
A healthcare restructuring
Boston Scientific is initiating a three-year restructuring plan. This initiative will involve significant changes to its production processes and supply chain operations. The medical device maker aims to optimize its manufacturing and delivery systems.
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
Hugo Boss investors shun Mike Ashley’s takeover bid
Mike Ashley's swoop on Hugo Boss marks the latest move in his aggressive spate of empire building - Eddie Keogh/Reuters Hugo Boss investors have shunned Mike Ashley's £2.3bn takeover bid for the German fashion giant. Mr Ashley has been forced to extend the acceptance …
BOSS
main company
Sharemaestro market context
Trend signal active
52 weeks -11.3% · Next-week setup negative 45.0%
What Are Wall Street Analysts' Target Price for Boston Scientific Stock?
Boston Scientific sign at manufacturer of medical devices Silicon Valley office By MichaelVi Marlborough, Massachusetts-based Boston Scientific Corporation (BSX) is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. With a market capitalization of approximately $68.5 billion, the company …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Mizuho cuts Boston Scientific stock price target on procedure declines
Mizuho lowered its price target for Boston Scientific (NYSE: BSX) to $60 from $70 due to declines in U.S. WATCHMAN stand-alone procedures and a revised electrophysiology outlook. Despite better-than-expected Q2 revenue, the company has cut its full-year organic top-line outlook twice, leading other firms …
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
Boston Scientific (BSX) Stock Sees Modest Fair Value Cut As Watchman Concerns Reset Expectations
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Earnings call transcript: Boston Scientific cuts 2026 outlook as shares fall in Q2 2026
Boston Scientific exceeded Q2 2026 earnings and revenue forecasts but saw its stock fall due to a lowered full-year outlook and concerns about its WATCHMAN and electrophysiology businesses. The company reported adjusted EPS of $0.86 and revenue of $5.44 billion, topping analyst estimates. Management …
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%
Boston Scientific: Q2 Earnings Snapshot
This article provides a brief snapshot of Boston Scientific's (BSX) Q2 earnings. No specific financial details are available in the provided content, as the article appears to be a placeholder or an incomplete data capture.
BSX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -51.2% · Next-week setup negative 42.4%